BRIEF-FDA approves 6-month primary end point for the Lutonix
September 19, 2016 at 18:04 PM EDT
* Approves 6 Primary efficacy end point in clinical trial is a composite of limb salvage and primary patency at 6 months
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.